SequelSEC

PharmaCyte Biotech, Inc. PMCB

Biological Products, (No Diagnostic Substances) · CIK 0001157075 · Fiscal year ends 0430

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-04-30
Operating income
-$6.85M
Fiscal year ended 2026-04-30
Free cash flow
Unavailable
Fiscal year ended 2026-04-30

PharmaCyte Biotech, Inc. (PMCB) reported revenue of $0 and net income of -$19.42M for the fiscal year ended 2026-04-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from PharmaCyte Biotech, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

PharmaCyte Biotech, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-302025-04-302024-04-302023-04-302022-04-302021-04-302020-04-302019-04-302018-04-302017-04-30
Revenue$0$0$0$0$0$0$0$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$6.85M-$4.38M-$8.52M-$6.46M-$4.39M-$3.62M-$3.83M-$4.10M-$6.98M-$4.44M
Net income-$19.42M$30.66M$333.76K-$4.32M-$4.24M-$3.55M-$3.83M-$4.07M-$6.83M-$4.44M
Research & development$391.30K$438.42K$407.43K$468.54K$690.94K$916.25K$301.22K$460.05K$2.00M$1.18M
Weighted-average diluted sharesshares 8.38Mshares 7.33Mshares 9.58Mshares 19.49Mshares 15.52Mshares 1.45Mshares 903.81Kshares 1.10Bshares 968.64Mshares 845.31M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0$0$0$0$0
Diluted EPS$-2.77$3.19$-1.80$-0.22$-0.27$-2.45UnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$4.91M$3.94M$6.11M$1.11M$1.09M$418.14K$1.16M$1.38M$1.82M$744.80K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

PharmaCyte Biotech, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-302025-04-302024-04-302023-04-302022-04-302021-04-302020-04-302019-04-302018-04-302017-04-30
Cash & equivalents$18.60M$15.17M$50.18M$68.04M$85.40MUnavailableUnavailableUnavailableUnavailableUnavailable
Total assets$46.75M$55.17M$59.90M$73.28M$90.62M$7.40M$6.17M$5.78M$6.41M$8.67M
Current assets$37.42M$22.38M$50.44M$68.15M$85.49M$2.28M$1.04M$653.40K$1.28M$3.54M
Total liabilities$11.77M$3.28M$20.39M$586.58K$704.37K$724.78K$1.08M$742.85K$644.17K$580.25K
Current liabilities$826.42K$2.91M$7.42M$586.58K$704.37K$724.78K$1.03M$742.85K$644.17K$580.25K
Total equity incl. NCI$33.29M$51.89M$27.65M$72.69M$89.92M$6.68M$5.09M$5.04M$5.77M$8.09M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$271.10K$399.20K$389.37K$128.28K$205.36K$172.26K$185.84K$121.88K$352.62K$365.60K

Cash flow

PharmaCyte Biotech, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-302025-04-302024-04-302023-04-302022-04-302021-04-302020-04-302019-04-302018-04-302017-04-30
Operating cash flow-$5.15M-$2.98M-$2.15M-$3.79M-$4.12M-$3.33M-$2.34M-$2.88M-$5.08M-$3.34M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow$2.00M-$7.00M-$5.00M$0$0$0$0$0$0$0
Financing cash flow$6.58M-$25.03M-$10.71M-$13.56M$87.31M$4.64M$2.73M$2.34M$2.68M$4.88M
Net change in cash$3.43M-$35.01M-$17.86M-$17.36M$83.20M$1.31M$379.61KUnavailableUnavailableUnavailable
Stock-based compensation$892.50K$0$674.69K$7.33K$33.15K$194.26K$368.65K$293.33K$580.36K$420.48K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$401.62K$2.54M$28.20M$13.56M$0UnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

PharmaCyte Biotech, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-302025-04-302024-04-302023-04-302022-04-302021-04-302020-04-302019-04-302018-04-302017-04-30
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio45.28x7.68x6.80x116.18x121.38x3.14x1.01x0.88x1.99x6.10x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PMCB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-09-14View SEC filing
10-K · Filed 2026-07-29View SEC filing
10-Q · Filed 2026-03-17View SEC filing
10-Q · Filed 2025-12-18View SEC filing
10-Q · Filed 2025-09-15View SEC filing
10-K · Filed 2025-08-11View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2026-04-30

Difference 1685892 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2024-04-30

Difference 11867016 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.